HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Evaluation from a B-cell epitope-based chimeric protein for the serodiagnosis of tegumentary and visceral leishmaniasis.

Abstract
The diagnosis of leishmaniasis presents problems due to the variable sensitivity and/or specificity of tests. In addition, high levels of anti-parasite antibodies can remain after treatment, making it difficult to conduct a prognostic follow-up of patients. In this context, it is necessary to identify new candidates to be examined for the sensitive and specific diagnosis of the disease. In the present study, four Leishmania proteins, previously shown as antigenic for tegumentary leishmaniasis (TL), were evaluated, and their linear specific B-cell epitopes were predicted and used to generate a new gene codifying chimeric protein called ChimB, which was cloned, and the recombinant version was expressed, purified, and evaluated in ELISA (Enzyme-Linked Immunosorbent Assay) to diagnose TL and visceral leishmaniasis (VL). A total of 220 human serum samples were used, and, when ChimB was used, results showed sensitivity, specificity, and positive and negative predictive values of 100% for the diagnosis of both diseases; however, when using peptides, the sensitivity values reached from 28.0% to 57.3% and specificity varied from 16.3% to 83.7%. A soluble Leishmania extract (SLA) showed sensitivity and specificity values of 30.7% and 45.9%, respectively. The area under the curve (AUC) value for ChimB was 1.0, while for synthetic peptides, this value reached between 0.502 and 0.635, whereas for SLA, the value was of 0.589. Serological assays using sera samples collected before and after treatment showed significant reductions in the anti-ChimB antibody levels after therapy, suggesting a prognostic role of this recombinant antigen. In conclusion, preliminary data suggest the use from ChimB as a potential candidate for the diagnosis and prognosis of leishmaniasis.
AuthorsDanniele L Vale, Amanda S Machado, Fernanda F Ramos, Daniela P Lage, Camila S Freitas, Daysiane de Oliveira, Nathalia C Galvani, Gabriel P Luiz, Mirian I Fagundes, Bruna B Fernandes, João A Oliveira-da-Silva, Fernanda Ludolf, Grasiele S V Tavares, Nathalia S Guimarães, Ana T Chaves, Miguel A Chávez-Fumagalli, Unaí Tupinambás, Manoel O C Rocha, Denise U Gonçalves, Vívian T Martins, Ricardo A Machado-de-Ávila, Eduardo A F Coelho
JournalMicrobial pathogenesis (Microb Pathog) Vol. 167 Pg. 105562 (Jun 2022) ISSN: 1096-1208 [Electronic] England
PMID35513293 (Publication Type: Journal Article)
CopyrightCopyright © 2022 Elsevier Ltd. All rights reserved.
Chemical References
  • Antibodies, Protozoan
  • Antigens, Protozoan
  • Epitopes, B-Lymphocyte
  • Peptides
  • Recombinant Fusion Proteins
Topics
  • Animals
  • Antibodies, Protozoan
  • Antigens, Protozoan (genetics)
  • Enzyme-Linked Immunosorbent Assay (methods)
  • Epitopes, B-Lymphocyte (genetics)
  • Humans
  • Leishmania
  • Leishmaniasis (diagnosis)
  • Leishmaniasis, Visceral (diagnosis)
  • Peptides
  • Recombinant Fusion Proteins (genetics)
  • Sensitivity and Specificity
  • Serologic Tests (methods)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: